These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8988341)

  • 61. [Bisphosphonates: pharmacology and use in the treatment of osteoporosis].
    Kishimoto H
    Nihon Rinsho; 1998 Jun; 56(6):1531-6. PubMed ID: 9648477
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Disuse osteoporosis.
    Takata S; Yasui N
    J Med Invest; 2001 Aug; 48(3-4):147-56. PubMed ID: 11694954
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intrinsic mechanical behavior of femoral cortical bone in young, osteoporotic and bisphosphonate-treated individuals in low- and high energy fracture conditions.
    Zimmermann EA; Schaible E; Gludovatz B; Schmidt FN; Riedel C; Krause M; Vettorazzi E; Acevedo C; Hahn M; Püschel K; Tang S; Amling M; Ritchie RO; Busse B
    Sci Rep; 2016 Feb; 6():21072. PubMed ID: 26879146
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Effects of antiresorptive therapy on the structural and material properties of bone strength].
    Kishimoto H
    Clin Calcium; 2016 Jan; 26(1):107-15. PubMed ID: 26728537
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
    Ravn P; Clemmesen B; Riis BJ; Christiansen C
    Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
    Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
    Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Frith JC; Luckman SP; Coxon FP; Benford HL; Mönkkönen J; Auriola S; Chilton KM; Russell RG
    Bone; 1999 May; 24(5 Suppl):73S-79S. PubMed ID: 10321934
    [No Abstract]   [Full Text] [Related]  

  • 68. [Newly developed drugs to improve bone strength].
    Hagino H
    Clin Calcium; 2016 Jan; 26(1):99-105. PubMed ID: 26728536
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effect of dichloromethylene diphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat.
    Miller SC; Jee WS
    Anat Rec; 1979 Mar; 193(3):439-62. PubMed ID: 154858
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The use of bisphosphonates in the treatment of osteoporosis.
    Papapoulos SE; Landman JO; Bijvoet OL; Löwik CW; Valkema R; Pauwels EK; Vermeij P
    Bone; 1992; 13 Suppl 1():S41-9. PubMed ID: 1581119
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effects of binge alcohol exposure on bone resorption and biomechanical and structural properties are offset by concurrent bisphosphonate treatment.
    Callaci JJ; Juknelis D; Patwardhan A; Sartori M; Frost N; Wezeman FH
    Alcohol Clin Exp Res; 2004 Jan; 28(1):182-91. PubMed ID: 14745317
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Effects of bisphosphonate for quality and strength of bone].
    Murakami H; Kawahara N; Sakamoto J; Tawara D; Tomita K
    Nihon Rinsho; 2006 Sep; 64(9):1651-6. PubMed ID: 16972674
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
    Li B; Ling Chau JF; Wang X; Leong WF
    J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Application of anti-resorptive drugs for the treatment of osteoporosis].
    Takada J
    Nihon Rinsho; 2006 Feb; 64(2):385-91. PubMed ID: 16454196
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bone quality: an empty term.
    Sievänen H; Kannus P; Järvinen TL
    PLoS Med; 2007 Mar; 4(3):e27. PubMed ID: 17341126
    [No Abstract]   [Full Text] [Related]  

  • 76. Bisphosphonates: how do they work?
    Papapoulos SE
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bisphosphonates: an overview with special reference to alendronate.
    Vasikaran SD
    Ann Clin Biochem; 2001 Nov; 38(Pt 6):608-23. PubMed ID: 11732644
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Bone hyperresorption in multiple myeloma].
    Beaudreuil J; Orcel P
    Presse Med; 2000 Mar; 29(9):492-7. PubMed ID: 10745943
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Secondary osteoporosis UPDATE. Pathophysiology and management of cancer treatment-induced bone loss/fractures].
    Yoneda T
    Clin Calcium; 2010 May; 20(5):690-9. PubMed ID: 20445280
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.